Institute of Molecular and Cell Biology
A*STAR

SEMINAR ANNOUNCEMENT

We would like to invite you to attend this seminar hosted by Prof. Tan Soo Yong:

Date: 17 July 2014, Thursday
Time: 3:00PM – 4:30PM
Venue: Level 3, IMCB Seminar Room 3-46, Proteos, Biopolis

Speaker: Dr. Christopher Bunker, Vice President of Business Development, Advanced Cell Diagnostics, Inc., USA
Title: Breakthrough Technology for in situ RNA Detection

Advanced Cell Diagnostics has developed the RNAscope platform for robust and sensitive RNA in situ hybridization (ISH) and expression analysis in fixed tissue and cell specimens. RNAscope is a universal method enabling detection of essentially any RNA from any species in nearly any tissue. Proprietary oligo probe design algorithms and amplification method results in single-target specificity and single RNA molecule sensitivity. It is the most sensitive method available enabling routine RNA detection in FFPE and frozen tissues and fixed cell sample. RNAscope is a simple kit for use in manual or automated assays with chromogenic, fluorescence and multiplex detection. Digital quantification of RNAscope signal in fixed specimens can be achieved with ACD's SpotStudio software. Illustrations of the technology and its application will be presented.

Biography:
Christopher Bunker did his doctoral research investigating the function of oncogenic transcriptional regulatory proteins, c-Myc and Polycomb group (PcG) proteins in the modulation of chromatin structure to suppress gene expression in cancer cell culture model systems. Dr. Bunkers work to understand PcG function in human cancer models was conducted in the laboratory of Dr. Robert E. Kingston at Harvard University and Massachusetts General Hospital. Dr. Bunker continued work in cancer biology with a Leukemia Society of America postdoctoral fellowship at the University of California, San Francisco, where he investigated mechanism of cell cycle control in Drosophila melanogaster development. Following his postdoctoral fellowship, Dr. Bunker joined Genome Therapeutics Corporation (GTC) as a senior scientist in cancer functional genomics, where he established gene expression array studies to identify target genes of the p53 tumor suppressor. Dr. Bunker has since put his scientific knowledge to use in business development activities for ten years at Cell Signaling Technology and for the past three and a half years at Advanced Cell Diagnostics.

ALL ARE WELCOME *(No registration required)*